Paul J. Hastings Chairman and Chief Executive Officer
Mr. Hastings is the Chairman and CEO of OncoMed Pharmaceuticals. Prior to joining OncoMed in 2006, Mr. Hastings was President and Chief Executive Officer of QLT, Inc. Previous to that, Mr. Hastings served as President and Chief Executive Officer of Axys Pharmaceuticals, which was acquired by Celera Corporation in 2001. From 1999 to 2001, Mr. Hastings served as the President of Chiron BioPharmaceuticals, a division of Chiron Corporation. Prior to that, he was President and Chief Executive Officer of LXR Biotechnology. Mr. Hastings also held a series of management positions of increasing responsibility at Genzyme Corporation, including serving as President of Genzyme Therapeutics Europe as well as President, Genzyme Therapeutics. Mr. Hastings also served as Vice President, Marketing and Sales and General Manager, Europe for Synergen, Inc., and previously held a series of marketing and sales management positions with Hoffmann-La Roche.
He is currently Lead Director of Pacira Pharmaceuticals and Chairman of the Board at Proteon Therapeutics, serves as Vice Chairman of the Biotechnology Innovation Organization (BIO) and serves on the board of the California Life Sciences Association. Mr. Hastings was recently on the board of directors of Relypsa, Inc. ( acquired by Galenica), was Chairman of the Board of Proteolix (sold to Onyx Pharmaceuticals in 2010), and served on the board of ViaCell (sold to Perkin-Elmer in 2007).
Mr. Hastings received a Bachelor of Science degree in pharmacy from the University of Rhode Island.
John Lewicki, Ph.D. Executive Vice President, Research and Development
From 1983 to 2000, John Lewicki served in various capacities at Scios, Inc., where he managed the company's research organization across diverse therapeutic areas. Among his many achievements with that organization was the co-discovery of Natrecor™, an FDA approved drug for congestive heart failure. Most recently, Dr. Lewicki was Senior Vice President, Research and Development of an early-stage biotechnology company working in the infectious disease field.
Dr. Lewicki received his Ph.D. in Physiology/Pharmacology from U.C. San Diego and conducted his post-doctoral training at University of Virginia and Stanford University. He is the author or co-author of more than 70 research papers and book chapters and is listed as an inventor on over 30 issued U.S. patents.
Austin Gurney, Ph.D. Senior Vice President, Molecular and Cellular Biology and co-Chief Scientific Officer
Austin Gurney joined OncoMed Pharmaceuticals at its founding as Vice President of Molecular and Cellular Biology. Prior to OncoMed, Dr. Gurney worked at Genentech where his research contributed to the discovery of numerous growth factors and cytokines. He has authored or co-authored more than 60 papers and is listed as an inventor on over 600 patents related to therapeutic applications in immunology and cancer. Dr. Gurney has two decades of experience in biotechnology and in the development of novel therapeutics.
Dr. Gurney conducted his Ph.D. work at Case Western Reserve University. He completed post doctoral studies with Dr. Bryan Williams at the Cleveland Clinic, and at Genentech with Dr. David Goeddel.
Tim Hoey, Ph.D. Senior Vice President, Cancer Biology and co-Chief Scientific Officer
Dr. Timothy Hoey is Senior Vice President, Cancer Biology at OncoMed Pharmaceuticals. The Cancer Biology group is responsible for testing new drugs targeting cancer stem cells and translational research to discover biomarkers indicative of CSC frequency and patients most likely to respond to OncoMed therapeutic antibodies. Dr. Hoey previously served as Director, Biology Department at Amgen (San Francisco) and was responsible for characterization of oncogenes and development of drugs to target oncogene products. Prior to this he was Director, Biology Department at Tularik, responsible for Cancer and Immunology research.
Prior to joining Tularik, he performed post doctoral studies on the mechanisms of transcriptional regulation at U.C. Berkeley under Dr. Robert Tijian. Dr. Hoey received his Ph.D. from Columbia University, where he conducted research on regulation of gene expression and embryonic development with Dr. Michael Levine. Dr. Hoey is listed as a co-inventor on several patents and has authored or co-authored over 50 scientific publications.
Sunil Patel Chief Financial Officer, Senior Vice President, Corporate Development and Finance
Mr. Patel brings more than 19 years of biopharmaceuticals industry experience to OncoMed, leading finance, administration, corporate development, alliance management and strategic marketing activities for the company. He joined OncoMed in 2009 from BiPar Sciences where as Vice President, Corporate Development and Marketing he led the sale of that company to Sanofi. Previously, he held senior corporate development, marketing, and strategy positions with Allos Therapeutics, Connetics Corporation, Abgenix and Gilead Sciences.
Mr. Patel also served as a consultant with McKinsey & Company. Earlier in his career, he was a researcher at ZymoGenetics and ProCyte. Mr. Patel received his undergraduate degree in Chemistry at the University of California, Berkeley, and his master's degree in Molecular Bioengineering/Biotechnology at the University of Washington. Mr. Patel is also a member of the board of directors of Ligand Pharmaceuticals.
Alicia J. Hager, J.D., Ph.D. Senior Vice President and General Counsel
Dr. Hager is Senior Vice President and General Counsel of OncoMed Pharmaceuticals. Prior to her appointment as General Counsel, Dr. Hager served as OncoMed’s Vice President, Legal Affairs and Chief Patent Counsel. Dr. Hager joined OncoMed in 2008 from the international law firm of Morrison & Foerster LLP, where she served as IP counsel for a number of biotech and pharmaceutical clients. Earlier in her career, Dr. Hager was a patent agent at the law firm of Heller Ehrman White & McAuliffe LLP. Dr. Hager received her J.D. from Stanford Law School, with distinction, and her Ph.D. and A.M. in Chemistry from Harvard University. She received her A.B. in Chemistry from Occidental College.
Robert Stagg, Pharm.D. Senior Vice President, Clinical Research and Development
Dr. Stagg is a Pharm.D. with extensive experience in Oncology drug development. Dr. Stagg joined OncoMed from PDL BioPharma where he served as Vice President of Regulatory and Drug Safety and prior to that as Senior Medical Director. Prior to PDL BioPharma, Dr. Stagg had served in a variety of clinical research capacities including Senior Director, Clinical Research for Tularik, Inc., Vice President, Clinical Research for Coulter Pharmaceutical, Director, Clinical Research at Gilead Sciences, Inc. and Medical Monitor at Genentech, Inc.
Dr. Stagg received his Pharm.D. from the University of the Pacific and he subsequently did his residency and Oncology fellowship at the University of California, San Francisco (UCSF). Subsequently, he joined the faculty at UCSF where he was an Assistant Clinical Professor from July 1983 to January 1991. While at UCSF his primary focus was oncology clinical research
Leonardo Faoro, MD, MBA Vice President, Clinical Development
Dr. Faoro is a medical oncologist with extensive pharmaceutical oncology drug development experience. He joined OncoMed from Genentech, a member of the Roche Group, where he was the Global Clinical Leader for Avastin®(bevacizumab) for metastatic breast cancer indications. While at Genentech, Dr. Faoro also worked on Avastin in other indications, including non-small cell lung cancer, renal cell carcinoma, prostate cancer, and cervical cancer. In this role, he led the clinical development activities for Avastin in these indications.
Dr. Faoro received his medical degree from the Universidade Federal do Parana, Brazil, and subsequently completed medical residency in Internal Medicine at the Mayo Clinic followed by a fellowship in Medical Oncology at the University of Chicago. While in Chicago, Dr. Faoro worked in Dr. Ravi Salgia’s lab, focusing on signaling inhibitors, with targets such as protein kinase C, PARP, and c-Met, while continuing his clinical activities in the area of thoracic oncology. Dr. Faoro also earned an MBA from the University of California, Berkeley, as well as from Columbia University.
Jill Henrich Vice President, Regulatory Affairs
Jill Henrich joined OncoMed Pharmaceuticals, Inc. as Vice President, Regulatory Affairs in January 2009. Prior to joining OncoMed, Ms. Henrich was at PDL BioPharma, Inc., most recently as Executive Director of Regulatory Affairs and Quality Assurance. While there she provided strategic management and oversight for all internal and external regulatory interactions, Regulatory Operations/Corporate Document Control, Medical Writing and Quality Assurance and Compliance activities. In addition, she was the Global Regulatory Leader supporting corporate alliances/partnerships developing therapeutics for immune-mediated diseases, and as a member of the CMC Management Committee was responsible for the technical and strategic management of CMC plans, deliverables, and resources related to PDL's clinical and commercial products. Prior to joining PDL BioPharma, Inc., Ms. Henrich was the Senior Director of Regulatory Affairs at Corixa Corporation (formerly Coulter Pharmaceutical, Inc.), and held various positions in Research (Cell Genetics/Molecular Biology) and Regulatory Affairs at Genentech, Inc. from 1987 through 1997, where she maintained global regulatory responsibility for two approved marketed products and multiple products in various phases of development. Ms. Henrich received her Bachelor of Science degree in Biological Sciences/Microbiology from the University of Connecticut.
Ann Kapoun, Ph.D. Vice President, Translational Medicine
Ann Kapoun, Ph.D., was promoted to Vice President of Translational Medicine in 2011 and has led the Translations Medicine group at OncoMed as its Senior Director since 2007. The group is responsible for developing biomarker strategies and assays to demonstrate proof of principle in oncology trials. Dr. Kapoun’s expertise is in the clinical execution and implementation of biomarkers and patient stratification approaches. Dr. Kapoun previously spent 10 years building Biomarker and Translational Medicine programs. She served as Associate Director of Biomarker R&D in Clinical Pharmacology & Experimental Medicine at ALZA / Johnson & Johnson. Prior to that she was the Department Head of Biomarker R&D at Scios Inc., where she was responsible for their Biomarker and Pharmacogenomics programs in support of clinical trials. Dr. Kapoun received her Ph.D. from Indiana University, Bloomington, IN, and she has coauthored more than 30 scientific publications and patents.